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Abstract: The definition and enforcement of reference 
measurement systems, based on the implementation 
of metrological traceability of patient results to higher-
order (reference) methods and/or materials, together 
with a clinically acceptable level of measurement uncer-
tainty (MU), are fundamental requirements to produce 
accurate and equivalent laboratory results. The MU asso-
ciated with each step of the traceability chain should 
be governed to obtain a final combined MU on clinical 
samples fulfilling the requested performance specifica-
tions. MU is useful for a number of reasons: (a) for giv-
ing objective information about the quality of individual 
laboratory performance; (b) for serving as a manage-
ment tool for the medical laboratory and in vitro diag-
nostics (IVD) manufacturers, forcing them to investigate 
and eventually fix the identified problems; (c) for help-
ing those manufacturers that produce superior products 
and measuring systems to demonstrate the superiority 
of those products; (d) for identifying analytes that need 
analytical improvement for their clinical use and ask IVD 
manufacturers to work for improving the quality of assay 
performance and (e) for abandoning assays with demon-
strated insufficient quality. Accordingly, the MU should 
not be considered a parameter to be calculated by medi-
cal laboratories just to fulfill accreditation standards, 
but it must become a key quality indicator to describe 
both the performance of an IVD measuring system and 
the laboratory itself.
Keywords: measurement uncertainty; metrological trace-
ability; performance specifications; standardization.
Introduction
In the International Vocabulary of Metrology, the meas-
urement uncertainty (MU) is defined as a “parameter 
characterizing the dispersion of the quantity values being 
attributed to a measurand” [1]. It describes the interval 
within which the value of the measurand is assumed to 
lie with a stated level of confidence. If in the general use, 
the term “uncertainty” relates to the concept of doubt, in 
medical laboratory the knowledge of MU implies instead 
increased confidence in the validity of a measurement 
result [2, 3].
The knowledge of MU and the definition of its allow-
able limits for the clinical application of measurements 
represents one of the mainstays, together with the defi-
nition of reference measurement systems and the estab-
lishment of a proper post-market surveillance of in vitro 
diagnostics (IVD) quality, needed to produce standardized 
laboratory results suitable for clinical use [3]. Estimating 
and checking MU in medical laboratories is essential to 
understand its influence on measurement results and, 
ultimately, their clinical suitability. However, although 
all medical laboratories seeking ISO 15189 accreditation 
know that MU estimate is a specific requirement (clause 
5.5.1.4), few know what to do with the calculated MU [4].
How to calculate MU in medical 
laboratories
Historically, two approaches have been proposed for 
estimating MU: the so-called “bottom-up” and “top-
down” approaches [5]. The “bottom-up” approach 
is the model originally proposed by the “Guide to the 
Expression of Uncertainty of Measurement” (GUM) [6]. 
This model, usually employed by reference laborato-
ries to obtain accreditation according to ISO 17025 and 
15195 standards, is based on a comprehensive dissection 
of the measurement, in which each potential source of 
uncertainty is identified, quantified and then combined 
to generate the MU of the result using statistical propaga-
tion rules [2]. We previously described the application of 
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this approach to the enzyme measurements using IFCC 
reference measurement procedures [7]. The application 
of this approach in medical laboratories is however too 
complicated and has encountered many practical prob-
lems and  objections [8].
The “top-down” approach is simpler and represents a 
good alternative to the previous approach. It estimates MU 
of laboratory results by using internal quality control (IQC) 
data to derive the random components of uncertainty and 
commercial calibrator information. It is now officially 
endorsed by the ISO Technical Specification 20914 that 
provides a practical guidance to be applied in medical 
laboratory settings for the purpose of estimating MU of 
values produced by measurement procedures intended to 
measure biological measurands [9]. The inspiring concept 
behind this approach, described in Figure 1, relies on 
the definition of MU across the entire traceability chain, 
starting with the uncertainty of reference materials (uref), 
extending through the IVD manufacturers and their pro-
cesses for assignment of calibrator values and uncertainty 
(ucal) and ending with the random variability of measuring 
systems (uRw)1 [10]. In particular, uRw can be derived from 
IQC, while ucal must include all uncertainties introduced 
by the selected calibration hierarchy for the measurand 
beginning with the highest available reference down to 
the assigned value of the calibrator for the commercial 
IVD medical device, including the uncertainty of bias cor-
rection (ubias), if a not negligible bias has been detected 
and corrected by the manufacturer when implementing 
traceability.
Although reference material providers, IVD manu-
facturers and medical laboratories have different roles 
and independent tasks across the metrological traceabil-
ity chain, their performances contribute together to the 
MU of patient results [11]. The crucial point is that the 
estimated MU must be always combined at each level of 
the employed traceability chain. Particularly, the MU at 
the level of clinical samples (uresult) must be the combina-
tion of all uncertainty contributions accumulated across 
the entire traceability chain ( 2 2result cal Rwu [u u ],= √ +  where 
2 2 2
cal ref value assignment biasu [u u u , if any]= √ + + ). This refutes 
the common misconception that the simple reproducibil-
ity of a measurement result equals its overall MU. A correct 
estimate of MU of laboratory results is indeed not possi-
ble without ucal. In the European market, the information 
about ucal shall be provided on request to the professional 
end-users. Sometimes, calibrators are offered without 
uncertainty, but it is up to the laboratory professionals 
to pretend this information and, in case of unavailability, 
the corresponding material should be disregarded and 
replaced with some alternatives offering this information 
needed for the correct estimate of uresult. On the other hand, 
it is very important to define conditions for deriving uRw 
that should correspond to a within-laboratory reproduc-
ibility for a period (e.g. 6 consecutive months) sufficient 
to capture most changes to measuring conditions and sys-
tematic sources of uncertainty, such as those caused by 
different lots of reagents, different calibrations or different 
environmental conditions [9]. Characteristics of control 
material for estimating uRw have been defined and should 
be carefully considered, i.e. the material should be different 
from that used to check the correct alignment of the meas-
uring system, be commutable and with concentration(s) 
corresponding to the decision cut-point(s) employed in the 
medical application of the test [12].
We previously reported some practical examples on 
how medical laboratories can correctly calculate uresult. As an 
example, figure 1 of ref. [13] described the metrological trace-
ability chain and combined standard MU of Abbott Architect 
creatinine enzymatic assay. In particular, uRw was estimated 
as CV from 6-month consecutive measurement data of a 
serum-based fresh-frozen control material, randomly ana-
lyzed daily during our ordinary laboratory activity.
How to define maximum allowable 
MU
The ISO Technical Specification 20914 is also clear in 



















Figure 1: Sources of measurement uncertainty across the entire 
metrological traceability chain.
1 ISO/TS 20914:2019 defines uRw as “uncertainty component under 
conditions of within-laboratory precision” (i.e. the uncertainty for 
a given measuring system in the same laboratory over an extended 
time period that includes routine changes to measuring conditions, 
for example, lot changes of reagents, calibrators, instrument main-
tenance, etc.).
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for a result to be used in a medical decision: “for a given 
measuring system, estimating the uncertainty of the 
results produced is of very limited value unless it can be 
compared with the allowable MU based on the quality of 
results required for medical use” [9]. After the 1st Euro-
pean Federation of Clinical Chemistry and Laboratory 
Medicine (EFLM) Strategic Conference, held in 2014, objec-
tive criteria for defining analytical performance specifica-
tions (APS) became available. These criteria are based on 
three models: model 1, based on the effect of analytical 
performance on clinical outcomes; model 2, based on 
components of biological variation of the measurand; 
and model 3, based on state of the art of the measurement 
(defined as the highest level of analytical performance 
technically achievable) [14]. One revolutionary aspect of 
this approach was to emphasize that certain models are 
better suited for some measurands than for others, and 
the attention should therefore primarily direct toward the 
measurand and its biological and clinical characteristics 
[15]. Grading different levels of quality (i.e. minimum, 
desirable and optimum) for APS is also very important 
because it stimulates IVD manufacturers to work for 
improving the quality of assays to move, in case, from 
unacceptable or minimum to desirable performance [16].
For MU, the relevant goal that should be fulfilled is 
that related to the allowable random variability of patient 
results, as the correct trueness transfer along the metro-
logical traceability chain should allow the achievement 
of unbiased (or negligibly biased) results [17]. In a recent 
paper, we used serum creatinine as an example for the def-
inition of maximum allowable MU [18]. This measurand 
has a strict metabolic control so that the most appropriate 
model for deriving APS is that based on its biological vari-
ation. By using published data about the average intra-
individual biological variation (CVI) of serum creatinine 
(4.4%) [19] and the classical Fraser’s paradigm for deriv-
ing APS for random variability [20], APS for standard MU 
of serum creatinine measurement on clinical samples are 
3.3% (≤0.75 CVI, minimum quality), 2.2% (≤0.50 CVI, desir-
able quality) and 1.1% (≤0.25 CVI, optimum quality).
Once defined, APS cover the total MU budget (TBu) 
that should be fulfilled at the level of patient results. The 
achievement of TBu depends on the MU contributions of 
each step of the metrological traceability chain [11, 12]. 
Therefore, it is essential to accurately define the entity of 
all those contributions and how much of the TBu is used 
across the different steps of traceability chain. We pre-
viously recommended that specific MU limits at differ-
ent levels of the traceability chain should be defined as 
fractions of allowed TBu; in particular, we conventionally 
recommended that no more than one third of TBu should 
be consumed by uref and ≤50% of TBu used by ucal. The 
remaining MU should be available for uRw as a margin to 
fulfill TBu [11, 12].
The uref represents the first contribution to the TBu. 
Due to uncertainty propagation in the calibration hierar-
chy, uref may significantly affect the MU of patient results. 
It is therefore intuitive that it should be markedly lower 
than APS for TBu. Continuing to use serum creatinine as 
an example, Figure 2 reports how to derive the allowable 
limits for the standard MU of higher-order references in 
order to not exceed with a high probability TBu at the level 
of clinical samples [18].
The role of IVD manufacturers is to identify higher-
order metrological references and, based on them, to 
define a calibration hierarchy to assign traceable values 
to system calibrators and estimate their MU [21]. The 
basic paradigm here is that, if present in a not negligible 
amount, a systematic error (bias) should be appropriately 
eliminated by adjusting the value assigned to the calibra-
tor, while the overall MU increases because of the ubias 
contribution [22]. In addition to ubias, the manufacturer 
must also combine uref. Once estimated, ucal should be 
compared with MU limits, which represent a proportion, 
e.g. 50%, of the TBu allowed for clinical laboratory results 
(Figure 2). Keeping ucal to a level fulfilling clinical needs 
is however a highly disregarded issue [13, 23–25]. When 
higher-order references do not exist, commercial calibra-
tors are usually value-assigned by manufacturers using 
in-house procedures. However, even in this case, end-user 
calibrator assigned values will have an MU that contrib-
utes to the uresult. In these circumstances, ucal will simply 
correspond to uvalue assignment (see description in the section 
“How to calculate MU in medical laboratories”), with no 
contribution from uref and ubias.
In a previous paper, we provided simulations about 
the status of the uncertainty budget for some measurands 
[11]. The indicated approach should now be applied to 
each analyte measured in the medical laboratory to verify 
if the status of the uncertainty budget of its measurement 
associated with the selected metrological traceability 
chain is suitable for clinical application of the test.
How to deal with bias on clinical 
measurements
In the traceability framework, medical laboratories should 
rely on the IVD manufacturers who must ensure trace-
ability of their measuring systems to the highest available 
references. Therefore, regular estimation of bias by the 
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end-user laboratory is not required. As the IVD measuring 
system is CE (“Communautés Européennes”)-marked and 
correct alignment to higher-order references is expected, 
laboratories should just consider the MU of the value 
assigned to the calibrator (that should include the ubias, if 
any) and combine it with uRw to obtain uresult. Appearance 
of a medically unacceptable measurement bias could be 
however shown by external quality assessment (EQA) 
surveillance, but caution needs to be exercised as only 
schemes fulfilling category I/IIA criteria are usable to this 
scope [13, 26]. If a medically significant bias is suspected 
during ongoing EQA surveillance, the bias against a refer-
ence (material or procedure) for that measurand should 
be estimated and the presence of a significant systematic 
error confirmed. Then, the bias value should be included 
in the estimate of MU of clinical samples [23, 27]. If the 
recalculated MU is not fulfilling the predefined APS, it is 
the responsibility of the manufacturer to take an imme-
diate investigation and eventually fix the problem with a 
corrective action (e.g. by improving the calibrator value-
assignment protocol). If unsolved by the manufacturer, 
the laboratory could introduce a correction factor for the 
detected bias. If so, the uncertainty of the correction factor 
needs to be estimated and included in the calculation of 
uresult. The use of bias correction factors by individual labo-
ratories is however not permitted by some national regula-
tions as this may alter the status of the measuring system, 
removing any responsibility from the manufacturer and 
depriving the system (and, consequently, the produced 
results) of the certification originally provided through 
CE marking. The introduction of correction factors by 
individual laboratories is also quite risky, as they are 
usually unaware of possible subsequent changes made 
by the manufacturer and may continue to use the correc-
tion factor even when the bias has been corrected in the 
reagent production stage. Therefore, we are not support-
ing the individual use of bias correction factors in daily 
practice, but we strongly believe that involved laborato-
ries should insist in order that the providing manufacturer 
quickly solves the issue. Table 1 summarizes the suggested 
sequential approach in case a clinically significant bias on 
patient results is suspected.
Why MU matters in medical 
laboratories
Suitability and selection of higher-order 
references
As discussed earlier, MU of higher-order references may 
significantly influence the fulfillment of APS for uresult. 
Using plasma glucose as an example, we demonstrated 
that at least four different metrological traceability chains 
can be used to transfer trueness from the measurand 
definition (according to the International System of Units 
[SI]) to commercial calibrators. By selecting one of these 
chains, IVD manufacturers may spend however very dif-
ferent amounts of the TBu in implementing traceability of 
Allowable limits for the standard MU
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Figure 2: Allowable limits for the standard measurement uncertainty (MU) of serum creatinine results on clinical samples (derived from 
the biological variation model) (uresult) and corresponding limits for creatinine higher-order references (materials or procedures) (uref) 
and commercial calibrator (ucal), expressed as a fraction of the total uncertainty budget (TBu).
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their measuring systems [21, 28]. Therefore, the quality of 
glucose measurement may be dependent on the type of 
traceability chain selected by manufacturers for trueness 
transferring, sometimes making it difficult to achieve APS 
for MU at the level of clinical samples. This is also true for 
other measurands, like serum creatinine [12, 18]. Accord-
ingly, when different options are available, in making 
choice IVD manufacturers should start to consider the 
suitability of higher-order references in terms of uref by 
selecting that with less impact on TBu [18].
Verification of quality of IVD medical devices
ucal may significantly impact the quality of IVD medical 
devices. However, in a number of studies we have shown 
that the manufacturer’s internal quality specifications 
to validate the calibrator traceability to higher-order 
references and then derive ucal are more often not estab-
lished on the basis of suitable APS [23–25]. For example, 
Abbott Diagnostics in a document released in August 2014 
informed customers that the internal release specification 
for serum creatinine calibrators was ±5% from the target 
value of National Institute of Standards and Technology 
(NIST) SRM 967a Level 1 [23]. However, this clearly does not 
fit with the aforementioned desirable APS for stand-
ard MU of creatinine measurements on clinical samples 
(±2.2%). Similarly, for serum total folate, Beckman Coulter 
in a technical bulletin released in 2011 informed custom-
ers that the internal release specification for their calibra-
tors was ±10% from the target value of WHO International 
Standard 03/178 [25]. Once again, this does not fit with 
APS for standard MU of folate on clinical samples, which, 
for assuring a clinically acceptable misclassification rate 
of individuals with suspected vitamin deficiency, should 
remain within ±2.5% [29]. Manufacturers should therefore 
start to conform their internal protocols of trueness trans-
fer from certified reference materials to commercial cali-
brators to the clinical value of tests and their APS defined 
according to the aforementioned models.
Providing evidence of clinically unsuitable 
results and stimulate work for improving the 
quality of assay performance
We previously reported examples in which deriving MU of 
clinical results provided evidence of clinically unsuitable 
results and stimulate manufacturers to work for improv-
ing the quality of assay performance [3]. In a first case, the 
performance of the immunoturbidimetric assay by Roche 
Diagnostics for measuring serum albumin, originally 
showing a too large bias and consequently an MU unable 
to fulfill APS for the clinical use of the test [27], was signif-
icantly improved in its metrological alignment resulting 
in the best recovery of the ERM-DA470k/IFCC reference 
material among 24 commercial assays for serum albumin 
[30]. Similarly, the status of glycated hemoglobin (HbA1c) 
traceability and associated MU, judged not enough in a 
detailed analysis [31], was later significantly improved 
permitting to fulfill APS for MU of HbA1c results [32].
Conclusions
In this paper, we provided an overview on how MU should 
be correctly estimated by medical laboratories and about 
the importance of this activity to guarantee reliability and 
quality of provided results. These concepts should apply 
to both marketed measuring systems and in-house proce-
dures, when CE-marked commercial alternatives are not 
available. Medical laboratories should estimate (by using 
the “top-down” approach) and validate (by suitable APS) 
the MU of each test at the level of patient results. This activ-
ity is useful for several reasons, summarized in Table 2, all 
aimed at improving the quality of patient results provided 
Table 1: Steps related to how to deal with bias on clinical 
measurements.
1.  Discover a medically unacceptable measurement bias during 
the external quality assessment (EQA) program (only schemes 
fulfilling category I/IIA criteria are however usable to this scope)
2.  If a medically significant bias (meaning a bias that does not fulfill 
the corresponding performance specifications) is suspected 
during the ongoing EQA surveillance, the bias against a reference 
(material or procedure) for that measurand should be estimated 
and the presence of a significant systematic error confirmed. Note 
that as reference may act any material or procedure positioned 
at the top of the corresponding traceability chain, even in the 
absence of high-order options
3.  The obtained bias value should be included in the estimate of 
measurement uncertainty (MU) of clinical samples
4.  If the recalculated MU is not fulfilling the predefined performance 
specifications, it is the responsibility of the manufacturer to take 
an immediate investigation and eventually fix the problem with a 
corrective action
5.  If unsolved by the manufacturer, the individual laboratory could 
introduce a correction factor for the detected bias. If so, the 
uncertainty of the correction factor needs to be estimated and 
included in the calculation of uresult. Note that the use of bias 
correction factors by individual laboratories may significantly 
alter the status of the commercial measuring system, removing 
the manufacturer’s responsibility and depriving the system of the 
certification originally provided through CE marking
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by medical laboratories and, ultimately, the patient safety 
[33]. Considering that MU should be used to evaluate both 
the performance of an IVD measuring system and the labo-
ratory itself, it should be added to the list of key quality 
indicators in all laboratories [34]. If needed, all attempts 
must be made to improve critical situations and, if the 
MU cannot be sufficiently reduced in order to fulfill APS, 
a decision can be made as to whether the measurement 
procedure is to be replaced with another performing better.
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